CORONAVIRUS NEWS
COVID-19: The Infection Challenging the World – BSMT sponsor update
This British Society for Microbial Technology (BSMT) virtual conference, held in conjunction with media partner Pathology in Practice, on 11–14 May, will be sponsored by 22 companies.
Novel SARS-CoV-2 neutralising antibodies identified
IONTAS and FairJourney Biologics have announced the identification of neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants.
Interleukin-6 test now available to help identify severe COVID-19
Beckman Coulter today has expanded claims for its CE-marked Access Interleukin-6 (IL-6) assay, an in vitro diagnostic test for the quantitative determination of IL-6 levels in human serum and plasma.
Commercial partnership to develop SARS-CoV-2 rapid antigen test
Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, has announced a commercial partnership with Mologic, a developer and manufacturer of lateral-flow and rapid diagnostic tests.
COVID-19: The Infection Challenging the World – BSMT programme update
Additions to the programme and sponsors for this important British Society for Microbial Technology (BSMT) virtual conference, which will be held on 11–14 May, have now been released. See the following for the latest details…
A new face for the BSMT, and a virtual meeting in May
The British Society for Microbial Technology (BSMT) will hold a virtual conference entitled ‘COVID-19 – The Infection Challenging the World' over four days in May. Click on this story for current details of the programme and commercial support.
Rapid antigen test confirmed to detect SARS-CoV-2 new variants
Avacta Group has announced that the AffiDX SARS-CoV-2 rapid antigen lateral-flow test detects the dominant new variants of the coronavirus, known as the B117 (Kent), variant, and the D614G variant, as well as the original strain.
Convenient and rapid antigen nasal test launched in the UK
Roche Diagnostics has launched a rapid antigen nasal test in the UK, with millions of kits available immediately to help businesses and organisations looking to reopen as lockdown restrictions are lifted.
Detection of IgG antibodies against four SARS-CoV-2 antigens
Bio-Rad Laboratories has announced the launch of the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel.
Increasing laboratory efficiency in a remote environment: a webinar
The SARS-CoV-2 pandemic has resulted in a challenging work environment. This has made the development and commercialisation of vaccines, treatments and critically needed PCR-based and serological diagnostics especially challenging.
A milestone and investment in COVID-19 testing capacity
Randox has processed its 10-millionth sample for the UK’s COVID-19 National Testing Programme, making it the first Pillar 2 testing laboratory to achieve this milestone, having invested £85 million since March 2020 in facilities and equipment.
Evaluation of SARS-CoV-2 lateral-flow test with clinical samples
Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, which show excellent performance in identifying patients with an infectious viral load and no false positive results.
Antimicrobial resistance: a problem with disinfectants
South African scientists warn of grave danger that disinfectant use against SARS-CoV-2 could be helping bacteria to become resistant to disinfectants.
A need to reconfigure and an opportunity to transform
The in vitro diagnostics industry has been at the forefront of the fight against SARS-CoV-2 and medicine’s response to cases of severe COVID-19 disease.
Rapid antigen test and support for SARS-CoV-2 testing
Avacta Group and Mologic have entered a partnership to market Avacta’s AffiDX SARS-CoV-2 lateral-flow rapid antigen test. Avacta will also support antigen testing in low- and middle-income countries by providing access to Avacta’s spike antigen test.
The infection challenging the world: a virtual meeting in May
The British Society for Microbial Technology (BSMT) will hold a virtual conference entitled ‘COVID-19 – The Infection Challenging the World' over four days in May. Click on this story for an update on the conference programme and commercial support.
High-throughput bead-assisted mass spectrometry test for SARS-CoV-2
Avacta Group has entered into a collaboration agreement with Bruker to evaluate the Affimer-based, bead-assisted mass spectrometry (BAMS) SARS-CoV-2 assay, developed with Adeptrix.
The infection that challenged the world: a date for your diary
The British Society for Microbial Technology (BSMT) is organising a virtual conference entitled ‘COVID-19 – The Infection that Challenged the World: Is Necessity the Mother of Invention?’
Launch of SARS-CoV-2 IgG II antibody test
Beckman Coulter has launched its Access SARS-CoV-2 IgG II assay in countries accepting the CE mark. The new Access SARS-CoV-2 IgG II assay quantitatively measures a patient’s level of antibodies in response to a previous SARS-CoV-2 infection.
SARS-CoV-2 antibody test to determine previous infection
Randox Laboratories has launched its new SARS-CoV-2 IgG test, utilising patented Randox Biochip Technology to simultaneously detect IgG antibodies that are reactive to both the spike receptor binding domain (RBD) and nucleocapsid protein (NP).
Featured Supplier
DiaSorin is an Italian multinational Group and a global leader in the market for in vitro diagnostics. DiaSorin is listed on the MTA (automated stock market) in the FTSE Italia Mid Cap Index, organized and managed by Borsa Italiana S.p.A
For over 40 years the Group has been developing, producing and commercializing diagnostic tests for a wide...
Upcoming Events
Lab Innovations 2021
NEC, Birmingham
3-4 November 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
